bullish
The Impact of COVID-19 and Shanghai Lockdown on China Healthcare
Xinyao has highlighted this Insight as a Top Pick
324 Views21 Apr 2022 09:05
We analyzed the impact of COVID/Shanghai lockdown on different sectors of China healthcare. This isn't just a battle over COVID,but also the future of China Yuan and the fortune or destiny of a nation
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- WuXi AppTec Co Ltd (2359.HK/603259.CH) 2022Q1 - Some Points Worth the Attention27 Apr 2022
- Hangzhou Tigermed Consulting (3347.HK/300347.CH) - The Business Model May Not Be a Safe Play25 Apr 2022
- China Healthcare Weekly (Apr.22) - TCM VBP Results, R&D Thinking Mode, Biotech Delisting24 Apr 2022
- Sino Biopharmaceutical (1177.HK) - Three “Golden Eggs” and the Risks Behind19 Apr 2022
- The Impact of America COMPETES Act on China Healthcare – Supply Chain Decoupling?13 Apr 2022
- The Concerns and Outlook About the Recent Rally in Traditional Chinese Medicine (TCM) Sector06 Jan 2022
x